Fumaderm®in daily practice for psoriasis: dosing, efficacy and quality of life

Sulforaphane Protects from T Cell-Mediated Autoimmune Disease by Inhibition of IL-23 and IL-12 in Dendritic Cells

(2014) J. Geisel et al.   JOURNAL OF IMMUNOLOGY

Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study

(2013) M. Berneburg et al.   BRITISH JOURNAL OF DERMATOLOGY

Glutathione-S-transferase T1 genotyping and phenotyping in psoriasis patients receiving treatment with oral fumaric acid esters

(2013) T. Gambichler et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Manufacturer's Response to Case Reports of PML

(2013) Marianne T. Sweetser et al.   NEW ENGLAND JOURNAL OF MEDICINE

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update

(2012) Alexander Nast et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling

(2012) Haiyan Peng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

(2011) J. Barker et al.   BRITISH JOURNAL OF DERMATOLOGY

Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions

(2011) Katrin Wallbrecht et al.   EXPERIMENTAL DERMATOLOGY

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

(2011) Kamran Ghoreschi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Dimethylfumarate Inhibits Angiogenesis In Vitro and In Vivo: A Possible Role for Its Antipsoriatic Effect?

(2011) Melissa García-Caballero et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Suppression of VEGFR2 Expression in Human Endothelial Cells by Dimethylfumarate Treatment: Evidence for Anti-Angiogenic Action

(2011) Markus Meissner et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression

(2011) Wolfram Hoetzenecker et al.   NATURE MEDICINE

Targeting glutathione by dimethylfumarate protects against experimental malaria by enhancing erythrocyte cell membrane scrambling

(2010) Mehrdad Ghashghaeinia et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Definition of treatment goals for moderate to severe psoriasis: a European consensus

(2010) U. Mrowietz et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Generation of pathogenic TH17 cells in the absence of TGF-β signalling

(2010) Kamran Ghoreschi et al.   NATURE

Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study

(2009) E.M. Wain et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

(2009) M. Lebwohl et al.   BRITISH JOURNAL OF DERMATOLOGY

The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo

(2009) Mandy J McGeachy et al.   NATURE IMMUNOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany

(2008) M. Augustin et al.   DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Dimethylfumarate Reduces Leukocyte Rolling in Vivo through Modulation of Adhesion Molecule Expression

(2007) Simone A. Rubant et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY